L3VLUP
ProSign in

COGT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

COGTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • COGT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCOGTVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 20202 holders, $8.0m30 holders, $18.4bn
Q1 20212 holders, $6.4m31 holders, $15.4bn
Q2 20212 holders, $17m30 holders, $12.7bn
Q3 20211 holders, $5.0m35 holders, $10.1bn
Q4 20211 holders, $5.1m28 holders, $12.4bn
Q1 20221 holders, $6.4m23 holders, $16.1bn
Q2 20221 holders, $9.0m25 holders, $18.1bn
Q3 20221 holders, $3.7m22 holders, $18.4bn
Q4 20223 holders, $11m28 holders, $18.4bn
Q1 20234 holders, $63m26 holders, $21.4bn
Q2 20233 holders, $93m27 holders, $24.7bn
Q3 20234 holders, $59m33 holders, $24.3bn
Q4 20233 holders, $35m32 holders, $28.6bn
Q1 20243 holders, $53m31 holders, $29.8bn
Q2 20244 holders, $97m29 holders, $33.4bn
Q3 20244 holders, $120m27 holders, $33.5bn
Q4 20244 holders, $47m26 holders, $28.5bn
Q1 20253 holders, $42m21 holders, $35.4bn
Q2 20253 holders, $43m21 holders, $32.3bn
Q3 20254 holders, $92m22 holders, $25.9bn
Q4 20259 holders, $1.3bn26 holders, $31.8bn
Q1 202611 holders, $1.6bn25 holders, $31.8bn
Q2 20267 holders, $1.6bn26 holders, $34.6bn
COGT

Cogent Biosciences Inc

Holders
4
Reported value
$47m
Buyers
1
Sellers
1

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 29 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only COGT (3)

Farallon Capital Management LLC, Freestone Grove Partners LP, Point72 Asset Management LP

Only VRTX (25)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →